Extracorporeal photopheresis and liver transplantation: Our experience and preliminary data

Extracorporeal Photochemotherapy/Photopheresis (ECP) is considered an immunomodulating therapy with several potential clinical applications. ECP was initially developed by Edelson et al. [1] as a treatment for cutaneous T-cell lymphoma (CTCL). In 1988, the use of ECP was approved by the U.S. Food and Drug Administration as standard therapy for the treatment of patients with advanced refractory CTCL [2]. Later, ECP was used in the treatment of several autoimmune T-cell-mediated diseases such as pemphigus vulgaris [3,4], systemic sclerosis [5,6], rheumatoid arthritis [7,8], Crohn's disease [9,10] and multiple sclerosis [11].

Source: Transfusion and Apheresis Science - July 10, 2017 Category: Hematology Authors: A. Mazzoni, C. Giampietro, I. Bianco, T. Grazzini, C. Nencini, C. Pileggi, F. Scatena, F. Filipponi, D. Ghinolfi, G. Catalano, G. Biancofiore, M.L. Bindi, L. Urbani Source Type: research